Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Gulo who wrote (14330)	11/23/2004 10:47:00 PM
From: charlyt	Read Replies (2) \| Respond to of 52153

"Never"? That is why I wanted some feedback on what the statement meant. The comparison may not constitute proof that the treatment triples survival, but isn't a difference that big (70 v 26 weeks) kinda hard to attribute to open-label bias or placebo effect? Or am I just completely wrong (it wouldn't be the first time) and the comparison is meaningless because of some factor I don't understand? It has happened several times where an apparent survival benefit in an uncontrolled early study compared to historical controls was NOT confirmed when a phase 3 controlled study was performed. Two examples off the top of my head are Biomira with Theratope in breast cancer and Isis Pharmaceuticals with Affinitak in NSCLC. Both appeared to have large survival benefits (many months) coming out of phase 2. Both showed nothing in phase 3.